Joao Incio
Overview
Explore the profile of Joao Incio including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
1520
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Incio J, Ligibel J, McManus D, Suboj P, Jung K, Kawaguchi K, et al.
Sci Transl Med
. 2018 Mar;
10(432).
PMID: 29540614
Anti-vascular endothelial growth factor (VEGF) therapy has failed to improve survival in patients with breast cancer (BC). Potential mechanisms of resistance to anti-VEGF therapy include the up-regulation of alternative angiogenic...
2.
Nia H, Liu H, Seano G, Datta M, Jones D, Rahbari N, et al.
Nat Biomed Eng
. 2017 Oct;
1.
PMID: 28966873
Solid stress and tissue stiffness affect tumour growth, invasion, metastasis and treatment. Unlike stiffness, which can be precisely mapped in tumours, the measurement of solid stresses is challenging. Here, we...
3.
Jung K, Heishi T, Incio J, Huang Y, Beech E, Pinter M, et al.
Proc Natl Acad Sci U S A
. 2017 Sep;
114(39):10455-10460.
PMID: 28900008
Antiangiogenic therapy with antibodies against VEGF (bevacizumab) or VEGFR2 (ramucirumab) has been proven efficacious in colorectal cancer (CRC) patients. However, the improvement in overall survival is modest and only in...
4.
Jung K, Heishi T, Khan O, Kowalski P, Incio J, Rahbari N, et al.
J Clin Invest
. 2017 Jul;
127(8):3039-3051.
PMID: 28691930
Current anti-VEGF therapies for colorectal cancer (CRC) provide limited survival benefit, as tumors rapidly develop resistance to these agents. Here, we have uncovered an immunosuppressive role for nonclassical Ly6Clo monocytes...
5.
Liu H, Naxerova K, Pinter M, Incio J, Lee H, Shigeta K, et al.
Clin Cancer Res
. 2017 Jun;
23(19):5959-5969.
PMID: 28600474
Angiotensin system inhibitors (ASI) can improve prognosis in multiple cancer types, including pancreatic ductal adenocarcinoma (PDAC). However, no study has examined the effect of ASIs alone or combined with adjuvant...
6.
Soares C, Incio J, Reis Ferreira M, Barbosa-Breda J, Paris L, Sandoval J
Acta Med Port
. 2017 Apr;
29(12):793-795.
PMID: 28425881
No abstract available.
7.
Rahbari N, Kedrin D, Incio J, Liu H, Ho W, Nia H, et al.
Sci Transl Med
. 2016 Oct;
8(360):360ra135.
PMID: 27733559
The survival benefit of anti-vascular endothelial growth factor (VEGF) therapy in metastatic colorectal cancer (mCRC) patients is limited to a few months because of acquired resistance. We show that anti-VEGF...
8.
Incio J, Liu H, Suboj P, Chin S, Chen I, Pinter M, et al.
Cancer Discov
. 2016 Jun;
6(8):852-69.
PMID: 27246539
Unlabelled: It remains unclear how obesity worsens treatment outcomes in patients with pancreatic ductal adenocarcinoma (PDAC). In normal pancreas, obesity promotes inflammation and fibrosis. We found in mouse models of...
9.
PlGF/VEGFR-1 Signaling Promotes Macrophage Polarization and Accelerated Tumor Progression in Obesity
Incio J, Tam J, Rahbari N, Suboj P, McManus D, Chin S, et al.
Clin Cancer Res
. 2016 Feb;
22(12):2993-3004.
PMID: 26861455
Purpose: Obesity promotes pancreatic and breast cancer progression via mechanisms that are poorly understood. Although obesity is associated with increased systemic levels of placental growth factor (PlGF), the role of...
10.
Fukumura D, Incio J, Shankaraiah R, Jain R
Microcirculation
. 2016 Jan;
23(3):191-206.
PMID: 26808917
With the current epidemic of obesity, a large number of patients diagnosed with cancer are overweight or obese. Importantly, this excess body weight is associated with tumor progression and poor...